McAdam LLC’s Vertex Pharmaceuticals VRTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-569
| Closed | -$258K | – | 472 |
|
|
2025
Q4 | $258K | Sell |
569
-171
| -23% | -$73.7K | 0.01% | 350 |
|
|
2025
Q3 | $290K | Buy |
740
+140
| +23% | +$58.5K | 0.01% | 310 |
|
|
2025
Q2 | $267K | Buy |
600
+84
| +16% | +$38.7K | 0.01% | 312 |
|
|
2025
Q1 | $250K | Sell |
516
-1,679
| -76% | -$782K | 0.02% | 288 |
|
|
2024
Q4 | $884K | Sell |
2,195
-441
| -17% | -$204K | 0.05% | 146 |
|
|
2024
Q3 | $1.23M | Buy |
2,636
+116
| +5% | +$55.7K | 0.07% | 118 |
|
|
2024
Q2 | $1.18M | Buy |
2,520
+488
| +24% | +$212K | 0.07% | 109 |
|
|
2024
Q1 | $849K | Buy |
2,032
+35
| +2% | +$14.8K | 0.05% | 127 |
|
|
2023
Q4 | $813K | Sell |
1,997
-170
| -8% | -$62.8K | 0.06% | 123 |
|
|
2023
Q3 | $754K | Buy |
2,167
+4
| +0.2% | +$1.4K | 0.06% | 130 |
|
|
2023
Q2 | $761K | Sell |
2,163
-60
| -3% | -$20.2K | 0.06% | 126 |
|
|
2023
Q1 | $700K | Sell |
2,223
-731
| -25% | -$219K | 0.06% | 128 |
|
|
2022
Q4 | $649K | Buy |
2,954
+186
| +7% | +$56.7K | 0.06% | 92 |
|
|
2022
Q3 | $801K | Buy |
2,768
+5
| +0.2% | +$1.44K | 0.09% | 106 |
|
|
2022
Q2 | $779K | Sell |
2,763
-170
| -6% | -$45.5K | 0.08% | 108 |
|
|
2022
Q1 | $765K | Sell |
2,933
-21
| -0.7% | -$4.98K | 0.07% | 91 |
|
|
2021
Q4 | $649K | Sell |
2,954
-385
| -12% | -$74.9K | 0.06% | 92 |
|
|
2021
Q3 | $606K | Buy |
3,339
+1,419
| +74% | +$277K | 0.07% | 88 |
|
|
2021
Q2 | $385K | Buy |
1,920
+210
| +12% | +$43.9K | 0.04% | 115 |
|
|
2021
Q1 | $367K | Hold |
1,710
| – | – | 0.05% | 106 |
|
|
2020
Q4 | $401K | Buy |
1,710
+679
| +66% | +$156K | 0.06% | 99 |
|
|
2020
Q3 | $281K | Buy |
1,031
+10
| +1% | +$2.76K | 0.05% | 104 |
|
|
2020
Q2 | $296K | Sell |
1,021
-34
| -3% | -$9.22K | 0.06% | 88 |
|
|
2020
Q1 | $251K | Buy |
1,055
+34
| +3% | +$7.8K | 0.07% | 83 |
|
|
2019
Q4 | $224K | Buy |
+1,021
| New | +$207K | 0.05% | 79 |
|
|
2019
Q3 | – | Sell |
-1,162
| Closed | -$213K | – | 87 |
|
|
2019
Q2 | $213K | Hold |
1,162
| – | – | 0.06% | 70 |
|
|
2019
Q1 | $214K | Sell |
1,162
-108
| -9% | -$19.9K | 0.07% | 66 |
|
|
2018
Q4 | $210K | Hold |
1,270
| – | – | 0.08% | 60 |
|
|
2018
Q3 | $244K | Buy |
1,270
+1,168
| +1,145% | +$208K | 0.09% | 53 |
|
|
2018
Q2 | $17K | Sell |
102
-848
| -89% | -$131K | 0.01% | 268 |
|
|
2018
Q1 | $155K | Buy |
+950
| New | +$155K | 0.07% | 72 |
|
Other funds holding VRTX
VCM
VPM
McAdam LLC's VRTX Position: Q1 2026 in Review
McAdam LLC sold out of Vertex Pharmaceuticals (VRTX) in Q1 2026, closing a stake of 569 shares — an estimated $258K sold.
McAdam LLC first reported a position in VRTX in Q1 2018 and held it in 31 quarters. The position peaked at $1.23M in Q3 2024. 1,687 funds tracked by Wall St. Rank hold VRTX as of Q1 2026.
- McAdam LLC reported no remaining Vertex Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
- McAdam LLC sold 569 Vertex Pharmaceuticals shares in Q1 2026, an estimated $258K.
- McAdam LLC first reported a position in Vertex Pharmaceuticals in Q1 2018 and held it in 31 quarters.
- McAdam LLC's Vertex Pharmaceuticals position peaked at $1.23M in Q3 2024.
- 1,687 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2026.
Based on McAdam LLC's 13F filing for Q1 2026, filed 8 May 2026.